Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Vascular function represents one of the most actively investigated clinical applications of fisetin. The rationale connects senescent cell accumulation in vascular endothelium with age-related arterial stiffening and endothelial dysfunction — key contributors to cardiovascular risk in older adults. A randomized clinical trial (NCT06133634) specifically studying fisetin for vascular function in adults aged 60–85 began enrollment in 2024. This represents one of the first rigorous human studies with functional vascular endpoints.
The Day Your Cells Start Working For You Again
Imagine waking up with clean energy, sharp focus, and resilient recovery. That's what happens when your mitochondria get what they need.
Detailed Evidence
BIOLOGICAL RATIONALE Aging is associated with accumulation of senescent endothelial cells in blood vessels, increased arterial stiffness (measured by pulse wave velocity), reduced flow-mediated dilation (FMD, a measure of endothelial function), and elevated vascular inflammatory markers. The hypothesis is that clearing senescent vascular cells with fisetin could improve endothelial function and reduce arterial stiffness. PRECLINICAL VASCULAR EVIDENCE In animal models, fisetin has demonstrated: reduced vascular inflammation in apoE-knockout mice (an atherosclerosis model); improved endothelium-dependent relaxation in aged mouse aortic rings; reduced expression of adhesion molecules (VCAM-1, ICAM-1) in endothelial cells exposed to inflammatory stimuli; and decreased oxidative stress markers in vascular tissue. THE NCT06133634 TRIAL This double-blind, randomized, placebo-controlled trial at the University of Minnesota studies fisetin's effects on vascular function in adults aged 60–85 without established cardiovascular disease. The design includes: fisetin at 20 mg/kg/day for 2 consecutive days per month over 3 months (intermittent senolytic protocol); primary endpoints of carotid-femoral pulse wave velocity (cfPWV) and brachial artery flow-mediated dilation (FMD); secondary endpoints including inflammatory biomarkers, senescence markers in blood, and safety parameters. This trial is significant because it represents rigorous methodology (double-blind, placebo-controlled), uses validated functional endpoints rather than just biomarkers, targets the specific population where vascular aging is clinically relevant, and follows the intermittent senolytic dosing protocol. RELATED EVIDENCE FROM OTHER SENOLYTICS The senolytic drug combination dasatinib + quercetin (D+Q) has shown preliminary evidence for improving vascular function in small pilot studies of individuals with diabetic kidney disease. These findings provide indirect support for the vascular senolytic hypothesis but cannot be directly extrapolated to fisetin, which may have different potency, tissue distribution, and mechanism specificity.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
Why Everything You've Tried for Energy Has Failed
Because none of it reached your mitochondria. Vitamins, adaptogens, superfoods — none of them address the core mechanism. Until now.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Can fisetin improve blood vessel function?
Preclinical studies show fisetin improved endothelium-dependent relaxation in aged mouse aortic rings and reduced vascular inflammation. A human trial (NCT06133634) is underway but results are not yet published.
What is the NCT06133634 trial?
A double-blind, randomized, placebo-controlled trial at the University of Minnesota studying fisetin's effects on vascular function in adults aged 60–85, using 20 mg/kg/day for 2 days per month over 3 months.
What vascular outcomes does fisetin target?
Primary endpoints are carotid-femoral pulse wave velocity (cfPWV, a measure of arterial stiffness) and brachial artery flow-mediated dilation (FMD, a measure of endothelial function).
Why target vascular senescence?
Senescent endothelial cells accumulate in aging blood vessels and contribute to arterial stiffness and impaired vasodilation through SASP-driven inflammation, increasing cardiovascular risk.
Does fisetin reduce arterial stiffness?
No published human data confirms this. The NCT06133634 trial is designed to measure pulse wave velocity as a primary endpoint, with results anticipated in 2026–2027.
How does fisetin affect endothelial cells?
In cell culture, fisetin reduced expression of adhesion molecules (VCAM-1, ICAM-1) in endothelial cells exposed to inflammatory stimuli and decreased oxidative stress markers in vascular tissue.
Is fisetin a substitute for blood pressure medication?
No. Fisetin is not approved or recommended for blood pressure management. Never replace prescribed medications with supplements without consulting your healthcare provider.
When will vascular trial results be available?
Results from the NCT06133634 trial are anticipated in 2026–2027. As of early 2026, no published results are available.
Has dasatinib+quercetin improved vascular function?
Preliminary D+Q data in diabetic kidney disease showed some improvement in vascular markers, providing indirect support for the senolytic vascular hypothesis but not directly applicable to fisetin.
What is pulse wave velocity?
Pulse wave velocity (PWV) measures arterial stiffness — how fast the blood pressure pulse travels through the circulatory system. Higher PWV indicates stiffer arteries and higher cardiovascular risk.
What is flow-mediated dilation?
Flow-mediated dilation (FMD) measures how well the brachial artery expands in response to increased blood flow, assessing endothelial function. Reduced FMD is a marker of vascular aging.
Does fisetin prevent heart attacks?
No. No clinical evidence suggests fisetin prevents heart attacks or cardiovascular events. The vascular trial measures functional endpoints, not clinical events.
Can exercise improve the same vascular endpoints?
Yes. Regular aerobic exercise reduces arterial stiffness by 10–25% in older adults — the most robust evidence for any vascular intervention, far stronger than fisetin.
Is fisetin safe for people with heart disease?
The NCT06133634 trial excludes adults with established cardiovascular disease. Safety data for fisetin in cardiac patients is insufficient. Consult a cardiologist before supplementing.
Could fisetin affect blood clotting?
Some flavonoids have anti-platelet effects. Fisetin-specific anticoagulant interactions have not been documented in humans. Individuals on blood thinners should exercise caution.
Key Research Facts
A randomized, double-blind, placebo-controlled trial (NCT06133634) is studying fisetin for vascular function in adults aged 60–85.
Strong EvidenceClinicalTrials.gov — NCT06133634
The trial uses fisetin at 20 mg/kg/day for 2 days per month over 3 months, with primary endpoints of pulse wave velocity and flow-mediated dilation.
Strong EvidenceClinicalTrials.gov — NCT06133634
Senescent endothelial cells accumulate in aging blood vessels and contribute to arterial stiffness and impaired vasodilation through SASP-driven inflammation.
Strong EvidenceKirkland & Tchkonia, J Internal Medicine — doi:10.1111/joim.13141
In aged mouse aortic rings, fisetin treatment improved endothelium-dependent relaxation, suggesting direct vascular benefit in preclinical models.
Moderate EvidenceKhan et al., Antioxidants & Redox Signaling — doi:10.1089/ars.2012.4901
Fisetin reduced expression of adhesion molecules VCAM-1 and ICAM-1 in endothelial cells exposed to inflammatory stimuli in cell culture.
Moderate EvidenceKhan et al., Antioxidants & Redox Signaling — doi:10.1089/ars.2012.4901
Preliminary D+Q data in diabetic kidney disease showed some improvement in vascular markers, providing indirect support for the senolytic vascular hypothesis.
Moderate EvidenceHickson et al., EBioMedicine — doi:10.1016/j.ebiom.2019.08.069
Arterial stiffness (measured by pulse wave velocity) is an independent predictor of cardiovascular events and all-cause mortality in older adults.
Strong EvidenceCardiovascular epidemiology — Multiple meta-analyses
No published human data demonstrates that fisetin reduces arterial stiffness or improves endothelial function.
Strong EvidenceLiterature review — PubMed search, 2026
The NCT06133634 trial represents the first rigorous human study with validated vascular functional endpoints for fisetin.
Strong EvidenceClinicalTrials.gov — NCT06133634
Regular aerobic exercise reduces arterial stiffness by 10–25% in older adults — the most robust evidence for any vascular intervention.
Strong EvidenceExercise physiology meta-analyses — Multiple systematic reviews
Citations & External Resources
ClinicalTrials.gov — Search: Fisetin
PubMed — Fisetin research
EBioMedicine — Yousefzadeh et al. 2018
NCT06133634 — Fisetin Vascular Function Trial
EBioMedicine — Hickson et al. 2019 (D+Q Senolytic Pilot)
J Internal Medicine — Kirkland & Tchkonia 2020 (Senolytic Review)
The Clock Is Ticking Inside Every Cell
Every day without mitochondrial support is a day your cells accumulate more damage, produce less energy, and age faster. The choice is yours.
Related Reading
Fisetin: The Complete Evidence-Based Guide
Fisetin Clinical Trials: Index of Human Studies
Fisetin & Healthy Aging: What Research Shows
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026